Molecure completes successful Secondary Public Offering (SPO) of approximately PLN50 million (USD12 million) with proceeds to be used to fund and build a first in class, sustainable pipeline of break through therapies
Molecure completes successful Secondary Public Offering (SPO) of approximately PLN50 million (USD12 million) with proceeds to be used to fund and build a first in class, sustainable pipeline of break through therapies
- Closingof equity offeringof 2,776,000 series H shares by private placement, offered within the authorised capital, at an issue price of PLN 18 per share
- Series H shares were subscribed for by 35 investors, new and existing institutional investors participated in the placement
- Investor interest was very high and the offer was oversubscribed
- The Company will leverage the recently completed capital raise to co-finance the implementation of Molecure’s strategic plans for 2023-2025
Warsaw, 21 July 2023. - Molecure S.A. (“Molecure”, WSE ticker: MOC), a biotechnology company discovering and developing drugs to the clinical stage, which leverages its globally unique expertise in
in medicinal chemistry and biology to explore and develop first-in-class small-molecule drugs that directly modulate protein activity and mRNA function to treat a wide range of incurable diseases, announced that it has successfully closed a SPO and entered into subscription agreements for all 2,776,000 H shares offered by way of private placement, within the authorized capital. The issue price was set at PLN 18, bringing the gross value of the offering to approximately PLN 50 million.
“We have successfully closed the H-share offering, which garnered significant interest from existing and new investors. We would like to thank all investors for participating in the offering and for the trust they have placed in Molecure. During the offering, we encountered a very good reception to our strategy and a positive evaluation of the Company’s growth potential, which translated into investor interest several times higher than the number of shares offered. Considering the current market conditions, we view the execution of the share issue as a remarkable achievement. The proceeds from the offering will be utilized to finance the advancement of Molecure’s clinical and research programmes, aimed at developing effective therapies to address numerous incurable diseases afflicting patients” - said Marcin Szumowski, CEO and shareholder of Molecure S.A.
The proceeds raised through the offering will co-finance the implementation of the Company’s strategic plans for 2023-2025, particularly the clinical development of its two flagship programmes, namely OATD-01 (a first-in-class chitotriosidase 1 (CHIT1) inhibitor for interstitial lung disease) and OATD-02 (a first-in-class dual arginase inhibitor for cancer).
Additionally, efforts will be intensified in a portfolio of early-stage programmes, including breakthrough small-molecule drug technology that modulates mRNA translation and therapeutics targeting previously unexplored protein targets. These initiatives are bolstered by advanced machine learning and generative artificial intelligence (GenAI) methods.
Molecure estimates that the capital expenditure associated with the strategy from mid-2023 to the end of 2025 will amount to approximately PLN 250 million.
Molecure is the only biotech company in Poland with two, proprietary first-in-class compounds at the clinical trial stage and is consistently building the value of these programmes. The company aims to secure at least one high-value partnership agreement for one of these clinical assets between 2023 and 2025, which could translate into tangible benefits for Shareholders.
“The primarybusiness objective of our strategy is to transformthe intellectual property value we have created into commercial success. We anticipate concluding a partnering agreement for at least one of our clinical assets before 2025, while also establishing commercial collaborations for programmes currently at an earlier stage of development. We are pleased that investors participating in the share offering have recognised our progress thus far and our strategy for futuregrowth. The funds raised from the share issue, combinedwith other sources of funding, will provide vital support for the successful and on-track progress of our programmes and further strengthens our negotiating position with partners” - added Marcin Szumowski.
LEGAL DISCLAIMER
This material is for information purposes only. It is published by the Company solely for the purpose of providing relevant information regarding the terms and conditions of the offer of H Shares. This material is in no way intended to promote, directly or indirectly, the offer, subscription or purchase of H Shares, nor does it constitute any advertisement or promotional material prepared or published by the Company for the purpose of promoting the H Shares, their subscription, purchase or offer or for the purpose of encouraging investors, directly or indirectly, to purchase or subscribe for H Shares. The Company has not published to date and does not intend to publish after the date of this current report any material for the purpose of promoting the Series H Shares, their subscription or purchase.
This material does not identify or suggest, and is not intended to identify or suggest, any risks [direct or indirect] that may be associated with an investment in the H Shares. Any investment decision to subscribe for or purchase H Shares pursuant to an offer, subscription or sale of such shares must be made solely on the basis of publicly available information.
This material does not constitute an invitation to underwrite, subscribe for or otherwise acquire or dispose of any securities in any jurisdiction. This material does not constitute a recommendation regarding an investor’s decision to offer, subscribe for or purchase H Shares. Each investor or potential investor should conduct its own investigation, analysis and evaluation of the business and data described in this material and publicly available information. The price and value of securities can go up as well as down. Past performance is not a guide to future performance.
For further information, please contact:
Media and retail investors:
Michał Wierzchowski, cc group
mob. +48 531 613 067
e-mail: michal.wierzchowski@ccgroup.pl
Institutional investors and sell-side analysts:
Katarzyna Mucha, cc group
mob. +48 697 613 712
e-mail: katarzyna.mucha@ccgroup.pl
MEDiSTRAVA Consulting (Financial PR)
David Dible, Frazer Hall, Sandi Greenwood
+44 (0)203 928 6900
molecure@medistrava.com
About Molecure
Molecure is a clinical stage biotechnology company that uses its world leading medicinal chemistry and biology capabilities to discover and develop first-in-class small molecule drug candidates that directly modulate the function of underexplored protein and RNA targets to treat multiple incurable diseases.
Molecure has generated a diverse pipeline of seven distinct programs with the support of leading academic life science institutions.
Molecure’s most advanced in-house drug candidate is OATD-01, a first in class dual chitinase inhibitor for the treatment of interstitial lung diseases, such as sarcoidosis and idiopathic pulmonary fibrosis, that is Phase II ready. A Phase II trial in patients with sarcoidosis is expected to start in early Q4 2023.
Our second proprietary candidate is OATD-02, an oral, potent and selective first in class, dual arginase inhibitor (ARG1 and ARG2) for the treatment of cancer, which advanced to Phase I clinical development in Q1 2023.
Molecure’s headquarters and laboratories are located in Warsaw, Poland with an additional laboratory facility in Łódź. The company is listed on the Warsaw Stock Exchange (ticker: MOC).
For more information, please visit https://molecure.com/
LinkedIn: Molecure | Twitter: @molecure_sa | YouTube: Molecure SA
